Scinai Immunotherapeutics (NASDAQ:SCNI) & Humacyte (NASDAQ:HUMA) Critical Review

Scinai Immunotherapeutics (NASDAQ:SCNI – Get Free Report) and Humacyte (NASDAQ:HUMA – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for Scinai Immunotherapeutics and Humacyte, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scinai Immunotherapeutics 1 0 0 0 1.00
Humacyte 1 1 6 0 2.62

Humacyte has a consensus target price of $4.48, suggesting a potential upside of 702.52%. Given Humacyte’s stronger consensus rating and higher possible upside, analysts plainly believe Humacyte is more favorable than Scinai Immunotherapeutics.

Institutional & Insider Ownership

58.4% of Scinai Immunotherapeutics shares are held by institutional investors. Comparatively, 44.7% of Humacyte shares are held by institutional investors. 6.0% of Scinai Immunotherapeutics shares are held by company insiders. Comparatively, 3.1% of Humacyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Scinai Immunotherapeutics has a beta of 2.27, suggesting that its share price is 127% more volatile than the S&P 500. Comparatively, Humacyte has a beta of 2.64, suggesting that its share price is 164% more volatile than the S&P 500.

Profitability

This table compares Scinai Immunotherapeutics and Humacyte’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Scinai Immunotherapeutics N/A N/A N/A
Humacyte -3,955.05% -612.88% -80.03%

Valuation & Earnings

This table compares Scinai Immunotherapeutics and Humacyte”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Scinai Immunotherapeutics $1.31 million 0.41 -$8.31 million $8.66 0.05
Humacyte $2.40 million 64.74 -$40.83 million ($0.44) -1.27

Scinai Immunotherapeutics has higher earnings, but lower revenue than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Scinai Immunotherapeutics beats Humacyte on 8 of the 14 factors compared between the two stocks.

About Scinai Immunotherapeutics

(Get Free Report)

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) is an Israel-based clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for autoimmune and inflammatory diseases. The company’s research is centered on treatments intended to modulate disease-related immune responses while potentially limiting systemic exposure and associated side effects. Scinai’s technology platform is based on NanoAb antibody fragments, which are designed to bind specific biological targets and may be suitable for local administration.

About Humacyte

(Get Free Report)

Humacyte, Inc. is a biotechnology company developing bioengineered human tissues for vascular repair and other medical applications. Its technology uses human vascular cells to create vessels that are processed to remove the cells, leaving an acellular structure designed for implantation. The company’s lead product, Symvess, is an acellular tissue-engineered vessel for treating extremity arterial injuries in adults when a patient’s own vein cannot be used for surgical revascularization. The U.S. Food and Drug Administration approved Symvess in December 2024.

Receive News & Ratings for Scinai Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scinai Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.